Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 2, 2005, Pages

  Empson, Marianne B ^a   Lassere, Marissa ^b   Craig, Jonathan C ^c   Scott, James R ^d  

^a Meditrina Ltd   (New Zealand)

^b ST GEORGE HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PREDNISONE;

CLINICAL TRIAL; DRUG COMBINATION; FEMALE; HUMAN; IMMUNOLOGY; META ANALYSIS; PREGNANCY; RECURRENT ABORTION; REVIEW;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUPUS COAGULATION INHIBITOR; PREDNISONE; PREGNANCY;

EID: 84921705962     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002859.pub2     Document Type: Article

References (126)

1. Branch DW, Peaceman AM, Druzin M, Silver RK, El-Sayed Y, Silver RM, et al. A multicentre, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The pregnancy loss study group. American Journal of Obstetrics and Gynecology 2000;182(1 Pt 1):122-7.
2. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. American Journal of Obstetrics and Gynecology 1992;166(5):1318-23.
3. Cowchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing group of the antiphospholipid antibody treatment trial. American Journal of Obstetrics and Gynecology 1997;176(5):1099-100.
4. Farquharson RG. Antiphospholipid syndrome in pregnancy: a controlled treatment trial. Journal of Obstetrics and Gynaecology 2001;21 Suppl 1:S22.
5. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics & Gynecology 2002;100(3):408-13.
6. von Dadelszen P, Kent N. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstetrics & Gynecology 2003;101(3):618.
7. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology 1996;174(5):1584-9.
8. Kutteh WH, Ermel LD. A clinical trial for the treatment of antiphospholipid antibody-associated recurrent pregnancy loss with lower dose heparin and aspirin. American Journal of Reproductive Immunology 1996;35(4):402-7.
9. Laskin CA, Bombardier C, Hannah ME, Mandel FP, Ritchie JW, Farewell V, et al. Prednisone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. New England Journal of Medicine 1997;337(3):148-53.
10. Merrill JT. Appropriate management of antiphospholipid-related pregnancy in women without lupus who have low titer autoantibodies. Current Rheumatology Reports 2001;3:269-70.
11. Pattison NS, Chamley LW, Birdsall M, Zanderigo AM, Liddell HS, McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. American Journal of Obstetrics and Gynecology 2000;183(4):1008-12.
12. Cohen H. Randomised trial of aspirin versus aspirin and heparin in pregnant women with the antiphospholipid syndrome. Annales de Medecine Interne 1996;147:44.
13. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314(7076):253-7.
14. Rai R, Regan L. Antiphospholipid antibodies and recurrent miscarriage. Acta Obstetricia et Gynecologica Scandinavica 1997;76 Suppl(167:4):6.
15. Rai RS, Cohen H, Regan L. Prospective randomized trial of aspirin versus aspirin + heparin in pregnant women with a history of recurrent miscarriage in association with antiphospholipid antibodies. Human Reproduction 1996;11:25.
16. Silver RK, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. American Journal of Obstetrics and Gynecology 1993;169(6):1411-7.
17. Silver RK, Sholl JS, MacGregor SN, Hobart JH, Neerhof MG, Hickman AH. Prospective evaluation of single (low-dose aspirin) vs combined (aspirin plus prednisone) therapy in the treatment of the antiphospholipid syndrome. Proceedings of 39th Annual Meeting of the Society for Gynecologic Investigation; 1992; San Antonio, Texas, USA. 1992:125.
18. Triolo G, Ferrante A, Ciccia F, Accardo-Palumbo A, Perino A, Castelli A, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis & Rheumatism 2003;48(3):728-31.
19. Tulppala M, Marttunen M, Soderstrom-Anttila V, Ailus K, Palosuo T, Ylikorkala O. Low dose aspirin in the prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Human Reproduction 1997;12(1):191.
20. Tulppala M, Marttunen M, Soderstrom-Anttila V, Foudila T, Ailus K, Palosuo T, et al. Low-dose aspirin in prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Human Reproduction 1997;12(7):1567-72.
21. Vaquero E, Lazzarin N, Valensise H, Menghini S, Di Pierro G, Cesa F, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. American Journal of Reproductive Immunology (Copenhagen) 2001;45(3):174-9.
22. Al-Momen AKM, Moghraby SA, El-Rab MOG, Gader AMA, al-Balla SR, Al, Meshari AA, al-Nuaim L. Pregnancy outcome in women with antiphospholipid antibodies. Clinical Rheumatology 1993;12(3):381-6.
23. Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. British Journal of Obstetrics and Gynaecology 1999;106(2):102-7.
24. Balasch J, Carmona F, Lopez-Soto A, Font J, Creus M, Fabregues F, et al. Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Human Reproduction 1993;8(12):2234-9.
25. Blumenfeld Z, Weiner Z, Lorber M, Sujov P, Thaler I. Anticardiolipin antibodies in patients with recurrent pregnancy wastage: treatment and uterine blood flow. Obstetrics & Gynecology 1991;78(4):584-9.
26. Boda Z, Laszlo P, Pfliegler G, Tornai I, Rejto L, Schlammadinger A. Low molecular weight heparin as thromboprophylaxis throughout pregnancy in heritable thrombophilic women. Clinical and applied thrombosis/hemostasis 1999;5(3):198-9.
27. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstetrics & Gynecology 1992;80(4):614-20.
28. Caruso A, De Carolis S, Ferrazzani S, De Santis L, Carducci B, Trivellini C, et al. Antiphospholipid antibodies in pregnant patients. International Journal of Immunopathology & Pharmacology 1997;10(2 Suppl):137-8.
29. Christiansen OB, Mathiesen O, Husth M, Rasmussen KL, Ingerslev HJ, Lauritsen JG, et al. Placebo-controlled trial of treatment of unexplained secondary recurrent spontaneous abortions and recurrent late spontaneous abortions with i.v. immunoglobulin. Human Reproduction 1995;10(10):2690-5.
30. Corosu R, Roma B, Cocola M, Marziali M. Antiphospholipid syndrome in obstetrics. Minerva Ginecologica 1998;50(1-2):9-13.
31. Costa M, Rossi E. Antiphospholipid antibodies and pregnancy. Annals of the New York Academy of Sciences 1999;876:383-6.
32. Cowchock FS, Wapner RJ, Needleman L, Filer R. A comparison of pregnancy outcome after two treatments for antibodies to cardiolipin. Clinical and Experimental Rheumatology 1988;6(2):200.
33. Cowchock S. Prevention of fetal death in the antiphospholipid antibody syndrome. Lupus 1996;5(5):467-72.
34. De Veciana M TP, Dattel B, Slotnick R, Abuhamad A. Dalteparin versus unfractionated heparin for prophylactic anticoagulation during pregnancy (abstract). American Journal of Obstetrics and Gynecology 2001;185(6 Suppl):S182.
35. Diejomaoh MF, Al-Azemi MM, Bandar A, Egbase PE, Jirous J, Al-Othman S, et al. A favorable outcome of pregnancies in women with primary and secondary recurrent pregnancy loss associated with antiphospholipid syndrome. Archives of Gynecology and Obstetrics 2002;266(2):61-6.
36. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin.[comment]. Arthritis & Rheumatism 2001;44(6):1466-7.
37. Franklin RD, Kutteh WH. Antiphospholipid antibodies (APA) and recurrent pregnancy loss: treating a unique APA positive population. Human Reproduction 2002;17(11):2981-5.
38. Geva E, Amit A, Lerner-Geva L, Lessing J.B. Prevention of early pregnancy loss in autoantibody seropositive women (letter). Lancet 1998;351(9095):34-5.
39. Gordon C, Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus 1998;7:429-33.
40. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997;6(6):509-13.
41. Gris JC, Neveu S, Tailland ML, Courtieu C, Mares P, Schved JF. Use of a low-molecular weight heparin (enoxaparin) or of a phenformin-like substance (moroxydine chloride) in primary early recurrent aborters with an impaired fibrinolytic capacity. Thrombosis and Haemostasis 1995;73(3):362-7.
42. Gris JC, Balducchi JP, Quere I, Hoffet M, Mares P. Enoxaparin sodium improves pregnancy outcome in aspirin-resistant antiphospholipid/antiprotein antibody syndromes. Thrombosis and Haemostasis 2002;87(3):536-7.
43. Hasegawa I, Takakuwa K, Goto S, Yamada K, Sekizuka N, Kanazawa K, et al. Effectiveness of prednisolone/aspirin therapy for recurrent aborters with antiphospholipid antibody. Human Reproduction 1992;7(2):203-7.
44. Kaaja R, Julkunen H, Viinikka L, Ylikorkala O. Production of prostacyclin and thromboxane in lupus pregnancies: effect of small dose of aspirin. Obstetrics & Gynecology 1993;81:327-31.
45. Kutteh WH, Yetman DL, Chantilis SJ, Crain J. Effect of antiphospholipid antibodies in women undergoing in-vitro fertilization: Role of heparin and aspirin. Human Reproduction 1997;12(6):1171-5.
46. Kwak JYH, Gilman-Sachs A, Beaman KD, Beer AE. Reproductive outcome in women with recurrent spontaneous abortions of alloimmune and autoimmune causes: preconception versus postconception treatment. American Journal of Obstetrics and Gynecology 1992;166(6 I):1787-98.
47. Lima F, Khamashta MA, Buchanan NMM, Kerslake S, Hunt BJ, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clinical and Experimental Rheumatology 1996;14(2):131-6.
48. Lockshin MD, Druzin ML, Qamar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. American Journal of Obstetrics and Gynecology 1989;160:439-43.
49. Mankuta D, Spitzer KA, Seaward G, Farine D, Ryan G, Clark-Soloninka C, et al. Prednisone does not affect the biophysical score in pregnant women. American Journal of Obstetrics and Gynecology 1999;180:S163.
50. Many A, Pauzner R, Carp H, Langevitz P, Martinowitz U. Treatment of patients with antiphospholipid antibodies during pregnancy. American Journal of Reproductive Immunology 1992;28(3-4):216-8.
51. Martin ME, Fernandez CJ. Prophylaxis of the spontaneous interruption of pregnancy (fetal miscarriage) in the antiphospholipid syndrome. Revista Espanola de Reumatologia 1997;24(3):95-100.
52. Mazzucconi MG, Dragoni F, Chistolini A, Peraino M, Paesano R, Di P, et al. Efficacy of low dose prednisone plus aspirin in preventing spontaneous abortions and/or fetal deaths due to antiphospholipid antibodies: results of a pilot study. Autoimmunity 1996;24(2):123-5.
53. McParland P. Low-dose aspirin in pregnancy. Contemporary Reviews in Obstetrics and Gynaecology 1993;5(1):30-8.
54. Mueller-Eckhardt G, Mallmann P, Neppert J, Lattermann A, Melk A, Heine, et al. Immunogenetic and serological investigations in nonpregnant and in pregnant women with a history of recurrent spontaneous abortions. Journal of Reproductive Immunology 1994;27(2):95-109.
55. Ogasawara M, Sasa H, Katano K, Aoyama T, Aoki K, Suzumori K. Recurrent abortion and moderate or strong antiphospholipid antibody production. International Journal of Gynecology & Obstetrics 1998;62(2):183-8.
56. Passaleva A, Massai G, D'Elios MM, Livi C, Abbate R. Prevention of miscarriage in antiphospholipid syndrome. Autoimmunity 1993;14(2):121-5.
57. Perino A, Vassiliadis A, Vucetich A, Colacurci N, Menato G, Cignitti M, et al. Short-term therapy for recurrent abortion using intravenous immunoglobulins: results of a double-blind placebo-controlled Italian study. Human Reproduction 1997;12(11):2388-92.
58. Quenby S, Farquharson R, Ramsden G. The obstetric outcome of patients with positive anticardiolipin antibodies: aspirin versus no treatment. 26 British Congress of Obstetrics and Gynaecology; 1992; Manchester, UK. 1992:443. [443]
59. Rai R, Regan L. Antiphospholipid antibodies, infertility and recurrent miscarriage. Current Opinion in Obstetrics and Gynecology 1997;9:279-82.
60. Rai R, Backos M, Baxter N, Chilcott I, Regan L. Recurrent miscarriage--an aspirin a day?. Human Reproduction 2000;15(10):2220-3.
61. Reece EA, Garofalo J, Zheng X-Z, Assimakopoulos E. Pregnancy outcome: influence of antiphospholipid antibody titer, prior pregnancy losses and treatment. Journal of Reproductive Medicine 1997;42(1):49-55.
62. Reznikoff-Etievant MF, Cayol V, Zou GM, Abuaf N, Robert A, Johanet C, et al. Habitual abortions in 678 healthy patients: investigation and prevention. Human Reproduction 1999;14(8):2106-9.
63. Ruffatti A, Orsini A, Di Lenardo L, Nardelli GB, Patrassi GM, Truscia D, et al. A prospective study of fifty-three consecutive calcium heparin treated pregnancies in patients with antiphospholipid antibody-related fetal loss. Clinical and Experimental Rheumatology 1997;15(5):499-505.
64. Sammaritano LR. Update on the management of the pregnant patient with antiphospholipid antibody. Current Rheumatology Reports 2001;3(3):213-21.
65. Scopelitis E, Wilson WA, Perez MC, Lynch A, Emlen W. Antiphospholipid antibodies in pregnancy. Annals of Internal Medicine 1994;121(7):547-8.
66. Semprini AE, Vucetich A, Garbo S, Agostoni G, Pardi G. Effect of prednisone and heparin treatment in 14 patients with poor reproductive efficiency related to lupus anticoagulant. Fetal Therapy 1989;4(Suppl 1):73-6.
67. Shefras J, Farquharson. Heparin therapy, bone density and pregnancy. 27th British Congress of Obstetrics and Gynaecology; 1995 July 4-7; Dublin. 1995:93. [93]
68. Sher G, Feinman M, Zouves C, Kuttner G, Maassarani G, Salem R, et al. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Human Reproduction 1994;9(12):2278-83.
69. Sher G, Matzner W, Feinman M, Maassarani G, Zouves C, Chong P, et al. The selective use of heparin/aspirin therapy, alone or in combination with intravenous immunoglobulin G, in the management of antiphospholipid antibody-positive women undergoing in vitro fertilization. American Journal of Reproductive Immunology (Copenhagen) 1998;40(2):74-82.
70. Spinnato J, Clark A, Pierangeli S, Harris N. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. American Journal of Obstetrics and Gynecology 1995;172:690-4.
71. Stern, K, Kornman L, Norris H, Hale L, Baker HWG. Heparin / aspirin do not help antiphospholipid-positive women with recurrent spontaneous abortion. Human Reproduction 2003;18(Suppl 1):55 xviii.
72. Takakuwa K, Arakawa M, Honda K, Imai T, Tamura M, Kurabayashi T, et al. Immunosuppressive therapy for recurrent aborters with positive antiphospholipid antibodies and alteration of 6ketoPGF1 alpha/TXB2 ratio. Journal of Perinatal Medicine 1997;25(6):509-11.
73. Vahid Dastjerdi M, Aleyasin A, Kashaf H, Marsoosi V, Aghahosscini A. The effect of acetyl salicylic acid and prednisolone before and during pregnancy in reducing unexplained recurrent abortions. Fertility and Sterility 1999;72:S203.
74. Yamamoto H, Kanaya M, Mori S, Inoue Y, Kiya T, Goto T, et al. The prevalence and treatment of recurred spontaneous abortions caused by autoimmunity. Japanese Journal of Fertility and Sterility 1994;39(4):25-30.
75. Carta G, Iovenitti P, Falciglia K. Recurrent miscarriage associated with antiphospholipid antibodies: prophylactic treatment with low-dose aspirin and fish oil derivates. Clinical & Experimental Obstetrics & Gynecology 2005;32(1):49-51.
76. Dendrinos S, Kalogirou I, Makrakis E, Theodoridis T, Mahmound EA, Christopoulou-Cokkinou V, et al. Safety and effectiveness of tinzaparin sodium in the management of recurrent pregnancy loss. Clinical and Experimental Obstetrics and Gynecology 2007;34(3):143-5.
77. Dendrinos S, Sakkas E, Makrakis E. Low-molecular-weight heparin versus intravenous immunoglobulin for recurrent abortion associated with antiphospholipid antibody syndrome. International Journal of Gynecology & Obstetrics 2009;104(3):223-5.
78. Ensom MH, Stephenson MD. Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy. Journal of the Society for Gynecologic Investigation 2004;11(6):377-83.
79. Goel N, Tuli A, Choudhry R. The role of aspirin versus aspirin and heparin in cases of recurrent abortions with raised anticardiolipin antibodies. Medical Science Monitor 2006;12(3):CR132-6.
80. Laskin CA, Spitzer KA, Clark CA, Crowther MR, Ginsberg JS, Hawker GA, et al. Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. Journal of Rheumatology 2009;36(2):279-87.
81. Mahmoud F, Diejomaoh M, Omu A, Abul H, Haines D. Effect of IgG therapy on lymphocyte subpopulations in the peripheral blood of Kuwaiti women experiencing recurrent pregnancy loss. Gynecologic and Obstetric Investigation 2004;58(2):77-83.
82. Malinowski A, Dynski MA, Maciolek-Blewniewska G, Glowacka E, Pawlowski T, Babula G. Treatment outcome in women suffering from recurrent miscarriages and antiphospholipid syndrome [Wyniki leczenia kobiet z nawracajacymi samoistnymi poronieniami i zespolem antyfosfolipidowym.]. Ginekologia Polska 2003;74(10):1213-22.
83. Merrill JT. Appropriate management of antiphospholipid-related pregnancy in women without lupus who have low titer autoantibodies. Current Rheumatology Reports 2001;3:269-70.
84. Noble LS, Kutteh WH, Lashey N, Franklin RD, Herrada J. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertility & Sterility 2005;83(3):684-90.
85. Rai RS, Regan L, Dave M, Cohen H. Prospective randomised trial of aspirin versus aspirin plus heparin in pregnant women with the antiphospholipid syndrome [abstract]. British Journal of Haematology 1996;93(Suppl 1):5.
86. Regan L. Steroids and antiphospholipid syndrome-related pregnancy loss (planned trial). ClinicalTrials.gov (http://clinicaltrials.gov/) (accessed 21 March 2006).
87. Shu J, Miao P, Wang RJ. Clinical observation on effect of Chinese herbal medicine plus human chorionic gonadotropin and progesterone in treating anticardiolipin antibody-positive early recurrent spontaneous abortion. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi//Chinese Journal of Integrated Traditional and Western Medicine 2002;22(6):414-6.
88. Stephenson MD, Ballem PJ, Tsang P, Purkiss S, Ensworth S, Houlihan E, et al. Treatment of antiphospholipid antibody syndrome (aps) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. Journal of Obstetrics & Gynaecology Canada: JOGC 2004;26(8):729-34.
89. Tulppala M, Marttunen M, Soderstrom-Anttila V, Ailus K, Palosuo T, Ylikorkala O. Low dose aspirin in the prevention of miscarriage in women with unexplained or autoimmune related recurrent miscarriage: effect on prostacyclin and thromboxane A2 production. Human Reproduction 1997;12(1):191.
90. Alderson P, Green S, Higgins JPT, editors. Medline search strategies for optimal sensitivity in identifying randomised clinical trials. Cochrane Reviewers’ Handbook 4.2.2 [updated December 2003]; 11a. Appendix B. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
91. Carreras LO, Perez G, Vega H, Casavilla F. Lupus anticoagulant and recurrent fetal loss: successful treatment with gammaglobulin. Lancet 1988;ii:393-4.
92. Chamley L, Duncalf A, Mitchell M, Johnson P. Action of anticardiolipin and antibodies to beta2-glycoprotein-1 on trophoblast proliferation as a mechanism for fetal death. Lancet 1998;352:1037-8.
93. Chamley L. Antiphospholipid antibodies: biological basis and prospects for treatment. Journal of Reproductive Immunology 2002;57(1-2):185-202.
94. Di Simone N, Ferrazzani S, Castellani R, De Carolis S, Mancuso S, Caruso A. Heparin and low-dose aspirin restore placental human chorionic gonadotrophin secretion abolished by antiphospholipid antibody-containing sera. Human Reproduction 1997;12(9):2061-5.
95. Di Simone N, Caliandro D, Castellani R, Ferrazzani S, De Carolis S, Caruso A. Low-molecular weight heparin restores in-vitro trophoblast invasiveness and differentiation in presence of immunoglobulin G fractions obtained from patients with antiphospholipid syndrome. Human Reproduction 1999;14(2):489-95.
96. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD004659.pub2]
97. Elder M, de Swiet M, Robertson A, Flloyd E, Hawkins D. Low-dose aspirin in pregnancy. Lancet 1988;i:410.
98. Ensom MH, Stephenson MD. Low-molecular-weight heparins in pregnancy. Pharmacotherapy 1999;19(9):1013-25.
99. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thrombosis and Haemostasis 1997;78(3):1008-14.
100. Francois A, Freund M, Daffos F, Remy P, Aiach M, Jacquot C. Repeated fetal losses and lupus anticoagulant. Annals of Internal Medicine 1988; Vol. 109:993-4.
101. Gasziou P, Irwig L. An evidence based approach to indivdualising treatment. BMJ 1995;311:1356-9.
102. Higashino M, Takakuwa K, Arakawa M, Tamura M, Yasuda M, Tanaka K. Anti-cardiolipin antibody and anti-cardiolipin beta-2-glycoprotein I antibody in patients with recurrent fetal miscarriage. Journal of Perinatal Medicine 1998;26(5):384-9.
103. Hirsh J, Warkentin T, Raschke R, Granger C, Ohman E, Dalen J. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(5):489S-510.
104. Kobayashi S, Tamura N, Tsuda H, Mokuno C, Hashimoto H, Hirose S. Immunoadsorbent plasmapheresis for a patient with antiphospholipid syndrome during pregnancy. Annals of the Rheumatic Diseases 1992;51(3):399-401.
105. Laurell A, Nilsson I. Hypergammaglobulinaemia, circulating anticoagulant, and biologic false positive Wassermann Reaction. Journal of Laboratory and Clinical Medicine 1957;49(5):694-707.
106. Lockwood C, Romero R, Feinberg R, Clyne L, Coster B, Hobbins J. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. American Journal of Obstetrics and Gynecology 1989;161:369-73.
107. Lubbe W, Butler W, Palmer S, Liggins G. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet 1983;i:1361-3.
108. Lubbe W, Liggins G. Lupus anticoagulant and pregnancy. American Journal of Obstetrics and Gynecology 1985;153:322-7.
109. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Annals of Internal Medicine 1994;120(6):470-5.
110. Lynch A, Byers T, Emlen W, Rynes D, Shetterly SM, Hamman RF. Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy. Obstetrics & Gynecology 1999;93(2):193-8.
111. Many A, Pauzner R, Carp H, Langevitz P, Martinowitz U. Treatment of patients with antiphospholipid antibodies during pregnancy. American Journal of Reproductive Immunology 1992;28:216-8.
112. Nelson-Piercy C. Low molecular weight heparin for obstetric thromboprophylaxis. British Journal of Obstetrics and Gynaecology 1994;101:9-17.
113. Nilsson I, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant ("antithromboplastin"). Acta Medicine Scandinavia 1975;197:153-9.
114. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Human Reproduction 1995;10(12):3301-4.
115. Rand JH, Wu XX, Guller S, Gil J, Guha A, Scher J, et al. Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion. American Journal of Obstetrics and Gynecology 1994;171(6):1566-72.
116. Rand JH, Wu XX, Andree H, Lockwood C, Guller S, Scher J, et al. Pregnancy loss in the antiphospholipid-antibody syndrome - a possible thrombogenic mechanism. New England Journal of Medicine 1997;337:154-60.
117. Rosove M, Tabsh B, Wasserstrum N, Howard P, Hahn B, Kalunian K. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstetrics & Gynecology 1990;75(4):630-4.
118. Salafia CM, Cowchock FS. Placental pathology and antiphospholipid antibodies: a descriptive study. American Journal of Perinatology 1997;14(8):435-41.
119. Sandercock P, Algra A, Anderson C, Bath P, Bereczki D, Berge E, et al. Stroke Group. About the Cochrane Collaboration (Collaborative Review Groups (CRGs)) 2004, Issue 4. Art. No.: STROKE.
120. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408-12.
121. Scott J, Branch D, Kochenour N, Ward K. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. American Journal of Obstetrics and Gynaecology 1988;159:1055-6.
122. Shefras J, Farquharson R. Bone density studies in pregnant women receiving heparin. European Journal of Obstetrics & Gynecology and Reproductive Biology 1996;65:171-4.
123. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop.[see comment]. Arthritis & Rheumatism 1999;42(7):1309-11.
124. Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective studies of the association between anticardiolipin antibody and outcome of pregnancy. Obstetrics & Gynecology 1995;86(4 Pt 1):555-9.
125. Yetman DL, Kutteh WH. Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies. Fertility and Sterility 1996;66(4):540-6.
126. Empson M, Lassere M, Craig J, Scott J. Recurrent pregnancy loss with antiphospholipid antibody: A systematic review of therapeutic trials. Obstetrics & Gynecology 2002;99(1):135-44.